Trial Profile
Xience V at WFUBMC: Real World Outcomes Using Second Generation DES.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel; Sirolimus
- Indications Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
- Focus Adverse reactions
- 07 Oct 2013 Status changed from recruiting to completed.
- 23 Oct 2012 Planned End Date changed to 1 Dec 2010 as reported in the abstract presented at the 24th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics..
- 23 Oct 2012 Planned initiation date changed to 1 Jul 2007 as reported in the abstract presented at the 24th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics..